Corcept Therapeutics

Yahoo Finance • 8 days ago

FDA Accepts New Drug Application for Corcept Therapeutics’s (CORT) Relacorilant

Corcept Therapeutics Incorporated (NASDAQ:CORT) is one of the Best Performing Long Term Stocks According to Analysts. On September 10, Corcept Therapeutics Incorporated (NASDAQ:CORT) announced that the FDA has accepted its new drug applica... Full story

Yahoo Finance • 17 days ago

Alger Russell Innovation Index Updates for Third Quarter 2025

NEW YORK, Sept. 15, 2025 /PRNewswire/ -- Fred Alger Management, LLC ("Alger"), a privately held growth equity investment manager, today announced the quarterly rebalancing of the Alger Russell Innovation Index ("Index"). Following the clos... Full story

Yahoo Finance • 22 days ago

Corcept's ovarian cancer treatment under FDA review

[Ovary cancer] Raycat/iStock via Getty Images * Corcept Therapeutics (NASDAQ:CORT [https://seekingalpha.com/symbol/CORT]) said that the U.S. FDA will review its marketing application for relacorilant, its oral therapy, for the treatment... Full story

Yahoo Finance • last month

Canaccord Genuity Maintains a Buy on Corcept Therapeutics (CORT), Retains a $137 PT

Corcept Therapeutics Incorporated (NASDAQ:CORT) is one of the most promising future stocks according to Wall Street analysts. On August 14, analyst Edward Nash of Canaccord Genuity maintained a Buy rating on Corcept Therapeutics Incorporat... Full story

Yahoo Finance • 2 months ago

Plant Breeding and CRISPR Plants Company Evaluation Report 2025 | Bayer, Syngenta, and BASF Lead with Advanced Breeding, Crop Protection, and Agricultural Innovation

Dublin, Aug. 15, 2025 (GLOBE NEWSWIRE) -- The "Plant Breeding and CRISPR Plants - Company Evaluation Report, 2025" report has been added to ResearchAndMarkets.com's offering. The Plant Breeding and CRISPR Plants Companies Quadrant is... Full story

Yahoo Finance • 2 months ago

Plant Biotechnology Company Evaluation Report 2025 | Bayer, Syngenta, and BASF Lead with Advanced Crop Protection, Seeds, and Sustainable Farming Solutions

Dublin, Aug. 14, 2025 (GLOBE NEWSWIRE) -- The "Plant Biotechnology - Company Evaluation Report, 2025" report has been added to ResearchAndMarkets.com's offering. The Plant Biotechnology Companies Quadrant is a comprehensive industry... Full story

Yahoo Finance • 2 months ago

Corcept therapeutics officer sells $2.5M in shares

William Guyer, Chief Development Officer at Corcept Therapeutics Inc (NASDAQ:CORT), sold 35,007 shares of common stock on August 8, 2025, for $71.77, totaling approximately $2.5 million. The sale was executed under a prearranged 10b5-1 t... Full story

Yahoo Finance • 2 months ago

Corcept therapeutics officer Lyon sells $393k in shares

Joseph Douglas Lyon, Chief Accounting & Technology Officer at Corcept Therapeutics (NASDAQ:CORT), sold 5,823 shares of common stock on August 1, 2025, for approximately $393,127. The shares were sold at a weighted average price of $67.51... Full story

Yahoo Finance • 2 months ago

Corcept Therapeutics Advances Pipeline Fueling Growth With Controlled Risk

Corcept Therapeutics Incorporated (NASDAQ:CORT) is one of the 11 Best Long Term Low Risk Stocks to Invest in. The company completes a key drug study and has submitted a new drug application to the U.S. FDA.Corcept Therapeutics Advances Pi... Full story

Yahoo Finance • 2 months ago

Corcept Advances Cancer Drug as Analysts Back Strong Growth Prospects

Corcept Therapeutics Incorporated (NASDAQ:CORT) is one of the 13 Best Low Risk High Growth Stocks to Buy. Analysts are reiterating their Buy rating for the stock amid advancements in ovarian cancer treatment.Corcept Advances Cancer Drug a... Full story

Yahoo Finance • 3 months ago

Corcept Submits NDA For Relacorilant To Treat Platinum-Resistant Ovarian Cancer

(RTTNews) - Corcept Therapeutics Incorporated (CORT), a commercial-stage biopharma company focused on cortisol modulation, has submitted a New Drug Application - NDA to the U.S. FDA for relacorilant in combination with nab-paclitaxel for t... Full story

Yahoo Finance • 3 months ago

Corcept seeks FDA approval for ovarian cancer treatment

[Cortisol molecular structure. 3D illustration] HT Ganzo/iStock via Getty Images * Corcept Therapeutics (NASDAQ:CORT [https://seekingalpha.com/symbol/CORT]) has submitted a marketing application to the U.S. FDA for its cortisol modulato... Full story

Yahoo Finance • 3 months ago

Piper Sandler reiterates Overweight rating on Corcept Therapeutics stock

Investing.com - Piper Sandler has reiterated an Overweight rating and $131.00 price target on Corcept Therapeutics (NASDAQ:CORT) following insights from an expert call on the company’s relacorilant treatment for ovarian cancer. The compa... Full story

Yahoo Finance • 3 months ago

Corcept therapeutics officer Guyer sells $7350 in shares

William Guyer, Chief Development Officer at Corcept Therapeutics Inc (NASDAQ:CORT), sold 100 shares of common stock on July 1, 2025, at a price of $73.505, for a total value of $7350. The transaction comes as Corcept, with a market capit... Full story

Yahoo Finance • 4 months ago

Corcept May 2025 slides: Revenue target of $900-950M amid pipeline advances

Introduction & Market Context Corcept Therapeutics (NASDAQ:CORT) presented its May 2025 corporate overview highlighting the company’s financial trajectory and expanding pipeline in cortisol modulation therapies. The presentation comes as... Full story

Yahoo Finance • 4 months ago

Corcept's mid-stage ALS study fails to meet main goal

[Microscopic of Neural network Brain cells] fatido/E+ via Getty Images Corcept Therapeutics (NASDAQ:CORT [https://seekingalpha.com/symbol/CORT]) said on Thursday that the mid-stage study of its cortisol modulator, dazucorilant, in patient... Full story

Yahoo Finance • 5 months ago

Why Corcept Therapeutics (CORT) Is Among the Best Performing Healthcare Stocks to Buy Now

We recently published a list of 11 Best Performing Healthcare Stocks to Buy Now. In this article, we are going to take a look at where Corcept Therapeutics Incorporated (NASDAQ:CORT) stands against other best performing healthcare stocks t... Full story

Yahoo Finance • 5 months ago

Corcept Therapeutics price target lowered to $135 from $150 at Truist

Truist analyst Joon Lee lowered the firm’s price target on Corcept Therapeutics (CORT) to $135 from $150 and keeps a Buy rating on the shares. The company’s Q1 Korlym revenue of $157.2M was softer than expected due to bandwidth issues with... Full story

Yahoo Finance • 5 months ago

Corcept Therapeutics (CORT): Among Billionaire Jim Simons’ RenTech’s Small-Cap Stock Picks with Huge Upside Potential

We recently published a list of Billionaire Jim Simons’ RenTech’s 10 Small-Cap Stock Picks with Huge Upside Potential. In this article, we are going to take a look at where Corcept Therapeutics Incorporated (NASDAQ:CORT) stands against Bil... Full story

Yahoo Finance • 5 months ago

Is Corcept Therapeutics Incorporated (CORT) Among the Best Guru Stocks to Buy According to Wall Street Analysts?

We recently published a list of 11 Best Guru Stocks to Buy According to Wall Street Analysts. In this article, we are going to take a look at where Corcept Therapeutics Incorporated (NASDAQ:CORT) stands against other Guru stocks to invest... Full story